Intellia Therapeutics (NTLA) Competitors $20.44 -0.10 (-0.49%) Closing price 04:00 PM EasternExtended Trading$20.43 -0.01 (-0.02%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. BEAM, CRSP, EDIT, TWST, MRUS, GRFS, RYTM, CYTK, ABVX, and RNAShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Twist Bioscience (TWST), Merus (MRUS), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Abivax (ABVX), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Editas Medicine Twist Bioscience Merus Grifols Rhythm Pharmaceuticals Cytokinetics Abivax Avidity Biosciences Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Which has more volatility and risk, BEAM or NTLA? Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Do analysts prefer BEAM or NTLA? Beam Therapeutics presently has a consensus target price of $46.40, suggesting a potential upside of 84.64%. Intellia Therapeutics has a consensus target price of $27.95, suggesting a potential upside of 36.74%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 2.93Intellia Therapeutics 2 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.52 Do insiders & institutionals have more ownership in BEAM or NTLA? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer BEAM or NTLA? In the previous week, Intellia Therapeutics had 16 more articles in the media than Beam Therapeutics. MarketBeat recorded 18 mentions for Intellia Therapeutics and 2 mentions for Beam Therapeutics. Intellia Therapeutics' average media sentiment score of 0.71 beat Beam Therapeutics' score of 0.66 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, BEAM or NTLA? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$60.27M42.18-$376.74M-$4.50-5.58Intellia Therapeutics$52.86M41.51-$519.02M-$4.69-4.36 Is BEAM or NTLA more profitable? Beam Therapeutics has a net margin of -661.31% compared to Intellia Therapeutics' net margin of -908.48%. Beam Therapeutics' return on equity of -43.15% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% Intellia Therapeutics -908.48%-57.48%-45.04% SummaryBeam Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.19B$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-4.3621.5485.6826.86Price / Sales41.51428.10583.23185.42Price / CashN/A46.3226.3031.10Price / Book2.3910.0613.256.72Net Income-$519.02M-$52.22M$3.30B$276.44M7 Day Performance18.36%5.84%4.70%3.13%1 Month Performance69.49%12.04%8.43%10.21%1 Year Performance14.57%26.13%88.01%40.35% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.5238 of 5 stars$20.44-0.5%$27.95+36.7%+14.2%$2.19B$52.86M-4.36600Trending NewsAnalyst UpgradeBEAMBeam Therapeutics3.0749 of 5 stars$23.91+4.1%$46.40+94.1%+10.6%$2.42B$63.52M-5.31510CRSPCRISPR Therapeutics1.744 of 5 stars$63.77+3.4%$71.50+12.1%+54.7%$5.80B$37.31M-11.74460EDITEditas Medicine4.2482 of 5 stars$3.52+8.6%$5.10+44.9%+12.4%$316.52M$32.31M-1.24230News CoverageTWSTTwist Bioscience3.7932 of 5 stars$26.99+0.3%$49.40+83.0%-26.5%$1.63B$312.97M-18.61990Analyst ForecastMRUSMerus1.1162 of 5 stars$93.67+36.0%$92.73-1.0%+82.1%$7.08B$36.13M-17.0337Analyst DowngradeGap UpHigh Trading VolumeGRFSGrifols3.7816 of 5 stars$9.93+1.1%$10.30+3.7%+7.7%$6.83B$7.81B8.4923,822Short Interest ↑RYTMRhythm Pharmaceuticals3.5455 of 5 stars$100.64+1.5%$106.64+6.0%+97.2%$6.68B$130.13M-33.44140CYTKCytokinetics3.842 of 5 stars$53.89+6.9%$75.71+40.5%+7.0%$6.45B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeABVXAbivax2.9101 of 5 stars$83.33+0.6%$102.14+22.6%+786.2%$6.30BN/A0.0061News CoverageAnalyst ForecastRNAAvidity Biosciences2.4846 of 5 stars$42.63-0.7%$68.32+60.3%-2.4%$6.22B$10.90M-11.97190 Related Companies and Tools Related Companies Beam Therapeutics Alternatives CRISPR Therapeutics Alternatives Editas Medicine Alternatives Twist Bioscience Alternatives Merus Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Cytokinetics Alternatives Abivax Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
